Introduction
============

Cardiovascular disease (CVD) represents a major health burden in China and throughout the world ([@b1-etm-0-0-7890]). Acute coronary syndrome (ACS) is the acute manifestation of ischemic heart disease, including ST-segment elevation myocardial infarction (STEMI), non-STEMI and unstable angina pectoris. ACS exhibits severe manifestations in Chinese populations and is associated with an estimated in-hospital mortality of 5% ([@b2-etm-0-0-7890]). Although percutaneous coronary intervention (PCI) is now widely available, certain ACS patients have a significant risk for the development of adverse cardiac events, even after PCI. Therefore, particular focus has been directed on the identification of novel biomarkers that may be used to predict the risk of future cardiovascular events, and aid the implementation of appropriate medical strategies for patients with ACS that may eventually improve disease prognosis. ACS is characterized by unstable atherosclerotic lesions. Inflammation has an important role in the progression of coronary atherosclerosis, plaque rupture and the incidence of thrombosis ([@b3-etm-0-0-7890]). CVD are accompanied by an increase in several inflammatory factors, including C-reactive protein, fibrinogen, white blood cell count, ferritin and ceruloplasmin, and by a decrease in the levels of specific proteins, including albumin, transferrin and anti-thrombin ([@b4-etm-0-0-7890]). Previous studies have confirmed that single inflammatory markers, including C-reactive protein ([@b5-etm-0-0-7890]), neutrophils ([@b6-etm-0-0-7890]), platelets ([@b7-etm-0-0-7890]), fibrinogen ([@b8-etm-0-0-7890]) and albumin ([@b9-etm-0-0-7890]), are associated with the prognosis of ACS, whereas the ratio of several single markers, e.g. the neutrophil-to-lymphocyte ratio ([@b10-etm-0-0-7890]), may also be associated with disease prognosis. The prognostic value of the fibrinogen-to-albumin ratio (FAR) has been studied in certain types of cancer, including esophageal and breast cancer ([@b11-etm-0-0-7890],[@b12-etm-0-0-7890]). However, to date, the association of the parameter FAR with the clinical outcome of patients with non-ST elevation (NSTE)-ACS has not been investigated ([@b13-etm-0-0-7890]). The purpose of the present study was to explore the association between 1-year disease outcomes and FAR levels of patients admitted with NSTE-ACS undergoing PCI.

Materials and methods
=====================

### Study design and setting

The design of the present study is illustrated in [Fig. 1](#f1-etm-0-0-7890){ref-type="fig"}. The study was based on a prospective observational cohort. A total of 1,352 consecutive NSTE-ACS patients (age range, 30--88 years; mean age, 62.5±10.6 years; male, 431, female, 921) were included in the cohort, who were recruited from the 1st of January 2015 to the 31st of December 2016. The patients were hospitalized and underwent PCI at the Shengjing Hospital of China Medical University (Shenyang, China), located in Northeastern China. Among these patients, 632 consecutive cases were diagnosed with non-STEMI and 720 were diagnosed with unstable angina pectoris. The clinical and procedural data were gathered from electronic medical records, image archives and communication systems of the interventional imaging data, and the surgical history of the PCI cases. The venous blood samples were obtained within 24 h of admission at room temperature, and the samples were used for analysis within 2 h of blood collection. The levels of albumin and fibrinogen were measured in the clinical laboratory of the Shengjing Hospital (Shenyang, China). Procedural data were extracted from the surgical history of patients who underwent PCI. The angiographic parameters were estimated visually and/or with the Picture Archiving and Communication Systems of the interventional imaging data (PHILIPS UNIQ FD10; <http://www.philips.com.cn/>, Neusoft PACS/RIS; <http://www.neusoft.com/cn?from=singlemessage>). Patients were followed up at 1, 3, 6 and 12 months after discharge. The clinical follow-up data were obtained from an outpatient clinic visit or telephone interviews with the patient\'s general practitioner/cardiologist, the patients themselves or their family. All enrolled patients were followed up for one year after discharge. All events were adjudicated and classified by two cardiologists. The present study complied with the Declaration of Helsinki, and was granted approval by the Shengjing Hospital of the China Medical University Research Ethics Committee (Shenyang, China). Written informed consent was formally obtained from all participants.

### Participants and procedures

In the present study, a total of 1,448 patients with non-STEMI and unstable angina were recruited. Patients taking corticosteroids or cytotoxic drugs, patients receiving thrombolytic therapy or heparin and patients with autoimmune diseases, hypohepatia or renal failure, cancer, hematological disorders, inflammatory or infectious diseases, pregnancy, surgery, trauma or hemorrhagic events, who were admitted within the previous 6 months of the initiation of the study, were excluded. The patients who were not treated with PCI and were not followed up for blood sample analysis were also excluded. As the use of heparin or other drugs on admission in STEMI patients may have an impact on the results of the study, the STEMI population was not included in the study, and at the same time, the patients treated with coronary artery bypass grafting (CABG) or those with prior CABG and patients unsuitable for revascularization were not included in the study. The final cohort consisted of 1,352 patients. FAR was defined as the concentration ratio of fibrinogen (mg/dl) to albumin (mg/dl) multiplied by 100. FAR levels were stratified by tertiles \[first tertile, \<7.106 (n=450); second tertile, 7.106--8.713 (n=451); third tertile, \>8.713 (n=451)\]. A high FAR (n=451) was defined as a value in the third tertile (8.713) and a low FAR (n=901) was defined as a value in the lower two tertiles (≤8.713).

### Definitions

Unstable angina was defined as the presence of chest pain originating from cardiac dysfunction that was deteriorating (i.e., more severe, prolonged or frequent than previous episodes of angina) or occurring at rest, without serological evidence of myocyte necrosis (i.e., no elevation of the serum concentration of troponin or of the levels of the MB isoenzyme of creatine kinase). Non-STEMI was defined as the presence of cardiac chest pain with serological evidence of myonecrosis in the absence of ST-segment elevation.

### Clinical end-points

The following endpoints were recorded: All-cause mortality, cardiac mortality, non-fatal myocardial reinfarction and unscheduled repeat revascularisation, which included the incidence of unscheduled repeat PCI and/or surgical bypass of target or non-target vessels.

### Statistical analysis

Quantitative variables were expressed as the mean ± standard deviation or median (interquartile range) and compared with an independent-samples t-test or the Mann-Whitney U-test. Categorical variables were represented as counts and proportions (%) and compared with a chi-squared test. The Cox proportional-hazard regression model was used to analyze the effects of variables on event-free survival. Kaplan-Meier survival curves were further constructed to assess the prognostic value of the FAR. Multivariate Cox analysis was used for the significant variables identified in the univariate analysis. These variables included age, sex, history of diabetes mellitus, history of hypertension, heart rate on admission, left ventricular ejection fraction (LVEF), leukocyte count, neutrophil count, platelet count, troponin-I on admission, creatinine, high-density lipoprotein (HDL), fibrinogen-to-albumin ratio, left main disease, three-vessel disease, and beta-blockers. The results are reported as hazard ratios (HRs) with the corresponding 95% confidence intervals (CIs). The accuracy of FAR for the prediction of major adverse cardiovascular events (MACEs) was assessed according to the area under the receiver-operating characteristic curve (ROC-AUC) with the MedCalc software for Windows version 11.4.2.0 (MedCalc Software). All of the tests were two-sided and P\<0.05 was considered to indicate statistical significance. All statistical analyses were performed with the SPSS version 19 (IBM Corp.).

Results
=======

### Baseline characteristics

The sample consisted of 1,352 NSTE-ACS patients who underwent PCI. The major clinical, demographic and angiographic features, description of PCI and discharge medications of patients according to their FAR are described in [Table I](#tI-etm-0-0-7890){ref-type="table"}. The patients of the high FAR group were older, with a lower percentage of female subjects, a higher incidence of diabetes mellitus and hypertension and a higher percentage of non-STEMI. Furthermore, these patients exhibited a higher incidence of left main disease and three-vessel disease and a higher frequency of beta-blocker administration. They further exhibited a higher heart rate on admission, a higher FAR and higher levels of troponin-I on admission, and elevated creatinine and fibrinogen levels. Finally, they presented with lower levels of HDL and albumin and a lower LVEF.

### Clinical Outcome

The clinical outcomes at the 1-year follow-up are provided in [Table II](#tII-etm-0-0-7890){ref-type="table"}. MACEs occurred in 127 patients (9.4%), comprising 67 (14.1%) in the low FAR group and 60 (13.3%) in the high FAR group. A total of 12 events of all-cause mortality, 10 events of cardiac mortality, 10 events of non-fatal myocardial reinfarction and 35 events of unscheduled repeat revascularisation were observed in the low FAR group. A total of 21 events of all-cause mortality, 17 events of cardiac mortality, 6 events of non-fatal myocardial reinfarction and 16 events of unscheduled repeat revascularisation occurred in the high FAR group. The data indicated that all-cause mortality and cardiac mortality were more frequent in the high FAR group (P\<0.05).

### Prognostic performance of different FAR levels in prediction of MACEs

The results of the Cox analysis are provided in [Table III](#tIII-etm-0-0-7890){ref-type="table"}. Univariate Cox analysis indicated that the FAR was an independent risk factor regarding all-cause mortality and of cardiac mortality of the NSTE-ACS patients. Multivariate Cox analysis was performed for the significant variables identified by the Univariate analysis. The data demonstrated that the FAR was an independent predictor of all-cause mortality (HR=2.223, 95% CI: 1.002--4.931, P=0.049). Kaplan-Meier curve analysis further revealed that patients with a higher FAR exhibited a higher incidence of all-cause mortality (P\<0.001; [Fig. 2](#f2-etm-0-0-7890){ref-type="fig"}) and cardiac mortality (P=0.001; [Fig. 3](#f3-etm-0-0-7890){ref-type="fig"}) than those with a lower FAR ([Figs. 2](#f2-etm-0-0-7890){ref-type="fig"} and [3](#f3-etm-0-0-7890){ref-type="fig"}). The cut-off points for the sensitivity and specificity of the FAR were estimated by performing ROC curve analysis ([Fig. 4](#f4-etm-0-0-7890){ref-type="fig"}). The FAR exhibited a sensitivity of 0.630 and a specificity of 0.726 for predicting MACEs ([Fig. 4](#f4-etm-0-0-7890){ref-type="fig"}). The ROC-AUC was 0.676 and the cut-off value was 9.114.

Discussion
==========

In the present study, a prospective analysis of 1,352 consecutive patients with NSTE-ACS treated with PCI was performed. This study found that the patients in the high FAR group were older and with a higher incidence of diabetes mellitus and hypertension. They exhibited higher levels of troponin-I on admission, elevated creatinine and a lower LVEF. These patients exhibited a higher incidence of left main disease and three-vessel disease. A previous study indicated that hypertension, diabetes, age, renal insufficiency and cardiac insufficiency are poor prognostic factors of coronary heart disease ([@b14-etm-0-0-7890]). Furthermore, the potential association between the FAR and MACEs in this cohort was explored. Cox analysis suggested that the FAR was independently associated with all-cause mortality in NSTE-ACS patients. The FAR exhibited an optimal accuracy for predicting MACEs, and its cut-off value in patients with NSTE-ACS undergoing PCI was 9.11, with a sensitivity of 0.630 and a specificity of 0.726. The results indicated that the FAR was an independent predictor of the 1-year clinical prognosis of NSTE-ACS patients. To date, a limited number of studies have been performed with regard to the association of the FAR with the incidence of CVD. A recent study reported that the FAR may be used as a biomarker of infarction to evaluate the severity of coronary artery disease in patients with STEMI ([@b15-etm-0-0-7890]). The FAR exhibited applicability in a similar manner to that for the outcome-differentiator SYNTAX score ([@b15-etm-0-0-7890]). To the best of our knowledge, the association of the FAR with the prognosis of NSTE-ACS has not been previously investigated. The present study suggested that the FAR may serve as a prognostic marker in NSTE-ACS.

Fibrinogen is an acute-phase protein ([@b4-etm-0-0-7890]). Plasma fibrinogen levels rise rapidly during the development of acute diseases, including severe bacterial infections, trauma and major surgery ([@b8-etm-0-0-7890]). Chronic low-grade inflammation further leads to elevated plasma fibrinogen levels, e.g. in the case of atherosclerosis ([@b16-etm-0-0-7890],[@b17-etm-0-0-7890]). Increased levels of fibrin have been confirmed in atherosclerotic lesions ([@b18-etm-0-0-7890],[@b19-etm-0-0-7890]). Fibrinogen is an important factor contributing to the coagulation process and a major component of thrombosis. In addition, this protein is considered an important inflammatory marker. High levels of fibrinogen are closely associated with the risk of CVD ([@b5-etm-0-0-7890],[@b20-etm-0-0-7890],[@b21-etm-0-0-7890]). The mechanisms by which fibrinogen leads to an increase in cardiovascular risk may be explained as follows: First, fibrinogen promotes platelet aggregation. In addition, increased fibrinogen levels promote the formation of fibrin and they increase plasma viscosity ([@b21-etm-0-0-7890],[@b22-etm-0-0-7890]). Finally, fibrinogen participates in inflammatory reactions and its levels are increased in inflammatory states ([@b5-etm-0-0-7890],[@b16-etm-0-0-7890],[@b17-etm-0-0-7890],[@b20-etm-0-0-7890]).

Albumin is a negative acute-phase protein produced in the liver, which is associated with the prognosis of several diseases. A low serum albumin (SA) level is predictive of the clinical prognosis of patients with coronary heart disease ([@b9-etm-0-0-7890],[@b23-etm-0-0-7890],[@b24-etm-0-0-7890]). Various studies have reported that hypoalbuminemia is associated with adverse outcomes, particularly in patients with CVD. This result may be explained by several mechanisms. SA exerts specific biological functions, including anti-oxidant and anti-coagulant activity, the maintenance of vascular integrity, the induction of vasodilatory effects, and the activation of toxin binding and cholesterol transport ([@b4-etm-0-0-7890],[@b25-etm-0-0-7890]). In addition, a decreased SA concentration may be associated with the development of inflammatory conditions ([@b26-etm-0-0-7890]--[@b28-etm-0-0-7890]) or inadequate nutritional intake ([@b27-etm-0-0-7890]).

Fibrinogen and albumin are closely associated with inflammation, and fibrinogen may modulate the inflammatory response by inducing the production of the pro-inflammatory cytokines interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-α from peripheral blood mononuclear cells ([@b8-etm-0-0-7890]). Recently, pro-inflammatory cytokines, particularly TNF-α and IL-1, have been reported to be associated with the development of hypoalbuminemia in patients ([@b28-etm-0-0-7890]). Certain studies have indicated that fibrinogen and albumin are closely associated with fibrinogen levels that correlate inversely with those of SA ([@b29-etm-0-0-7890],[@b30-etm-0-0-7890]). The interaction between albumin and fibrinogen results in impaired fibrinogen activity ([@b31-etm-0-0-7890]), while infusion of albumin may decrease coagulation competence during major surgery ([@b32-etm-0-0-7890]). Since fibrinogen and albumin exhibit a positive and negative correlation with the inflammatory response, respectively, their ratio may be correlated with inflammation. Fibrinogen and albumin are two proteins present in the serum, and it is suggested that the FAR is more convenient and effective compared with the combination of the two markers (fibrinogen and albumin) measured independently, and the FAR is used in clinical applications.

The FAR may reflect information on inflammation and may be used as a valuable serological marker. Karahan *et al* ([@b15-etm-0-0-7890]) reported that FAR may be used to evaluate the severity of coronary artery disease in patients with STEMI. Recent studies have indicated that the FAR is associated with the severity of coronary stenosis in STEMI patients and that it is an independent predictor of all-cause mortality that may be used as a prognostic indicator in patients with STEMI ([@b33-etm-0-0-7890]). The present study suggested that the FAR is an independent predictor of all-cause mortality in patients with NSTE-ACS undergoing PCI. A limited number of studies have been performed on the prognostic value of FAR in patients with ACS. The present results should be verified in future follow-up studies with larger sample sizes.

The present study has several limitations, including the single-center design, which may have introduced selection bias. Furthermore, the present study evaluated the SA and serum fibrinogen concentration only pre-operatively, and the patient samples were tested only once prior to PCI, which did not allow for the time-dependent assessment of the changes noted regarding the clinical and biochemical end-points. In addition, C-reactive protein (CRP) a commonly studied inflammatory factor, which is involved in multiple stress responses and serves as an important factor for the prognosis of cardiovascular disease ([@b5-etm-0-0-7890]). CRP was not included in the current study, which is a limitation. In addition, the subjects were patients with NSTE-ACS who underwent PCI and the STEMI population was not included. Patients treated with CABG or those who received prior CABG or were unsuitable for revascularisation were not included in the present study. Due to limited economic circumstances of certain patients, intermediate lesions and critical lesions were not subjected to fractional flow reserve detection, did not receive any PCI treatment, conservative medical treatment or regular follow-up and the present study did not include such patients. For the selected patients, the criteria for determining a successful PCI were the achievement of a minimum stenosis diameter reduction to \<20%, grade 3 thrombolysis in myocardial infarction flow assessed by angiography, angina pectoris eliminated or significantly alleviated, and improved abnormalities in the electrocardiogram. At our medical center, only \<15% of the population is subjected to intravascular ultrasound validation ([@b34-etm-0-0-7890]). Therefore, studies with a larger sample size are necessary in the future. Taken together, the results of the present study suggested that the FAR was able to predict the 1-year prognosis of patients with NSTE-ACS treated by PCI. Further multicenter studies are required to confirm the present results.
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###### 

Baseline clinical characteristics and periprocedural details.

  Variables                                  Low FAR (n=901)     High FAR (n =451)   P-value
  ------------------------------------------ ------------------- ------------------- -------------------------------------------------------
  Age (years)                                61.5±10.4           64.2±10.8           \<0.001^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Female (%)                               636 (70.6)          285 (63.2)          0.006^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Current/recent smoker                    355 (39.4)          164 (36.4)          0.279^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Diabetes mellitus                        224 (24.9)          158 (35.0)          \<0.001^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Hypertension                             578 (64.2)          319 (70.7)          0.016^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    MI                                       97 (10.8)           53 (11.8)           0.586^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    PCI                                      99 (11.0)           60 (13.3)           0.213^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Prior peripheral arterial disease        19 (2.1)            11 (2.4)            0.697^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    SBP (mmHg)                               140.4±20.2          139.6±22.5          0.462^[c](#tfn4-etm-0-0-7890){ref-type="table-fn"}^
    Heart rate (bpm)                         72 (64--80)         74 (67--83)         \<0.001^[b](#tfn3-etm-0-0-7890){ref-type="table-fn"}^
    LVEF (%)                                 61 (58--65)         61 (55--64)         0.010^[b](#tfn3-etm-0-0-7890){ref-type="table-fn"}^
    Leukocyte count (×10^9^/l)               7.2 (5.9--8.6)      7.7 (6.2--9.3)      0.001^[b](#tfn3-etm-0-0-7890){ref-type="table-fn"}^
    Neutrophil count (×10^9^/l)              4.7 (3.8--6.5)      5.2 (3.9--7.5)      \<0.001^[b](#tfn3-etm-0-0-7890){ref-type="table-fn"}^
    Platelet count (×10^9^/l)                201.5±58.4          215.6±63.9          \<0.001^[c](#tfn4-etm-0-0-7890){ref-type="table-fn"}^
    Troponin-I on admission (µg/l)           0.0 (0.0--0.5)      0.1 (0.0--1.0)      \<0.001^[b](#tfn3-etm-0-0-7890){ref-type="table-fn"}^
    Creatinine (µmol/l)                      72.0 (59.4--83.5)   73.0 (60.7--91.0)   0.005^[b](#tfn3-etm-0-0-7890){ref-type="table-fn"}^
    Total cholesterol (mmol/l)               4.5±1.2             4.4±1.1             0.167^[c](#tfn4-etm-0-0-7890){ref-type="table-fn"}^
    HDL (mmol/l)                             1.0 (0.8--1.2)      0.9 (0.8--1.2)      0.020^[b](#tfn3-etm-0-0-7890){ref-type="table-fn"}^
    LDL (mmol/l)                             2.8±1.0             2.8±1.0             0.531^[c](#tfn4-etm-0-0-7890){ref-type="table-fn"}^
    Triglycerides (mmol/l)                   1.6 (1.0--2.4)      1.5 (1.0--2.1)      0.072^[b](#tfn3-etm-0-0-7890){ref-type="table-fn"}^
    Fibrinogen (g/l)                         2.9±0.5             4.1±0.6             \<0.001^[c](#tfn4-etm-0-0-7890){ref-type="table-fn"}^
    Albumin (g/l)                            41.2±3.3            37.9±3.8            \<0.001^[c](#tfn4-etm-0-0-7890){ref-type="table-fn"}^
    FAR                                      7.1 (6.2--7.8)      10.3 (9.4--11.6)    \<0.001^[b](#tfn3-etm-0-0-7890){ref-type="table-fn"}^
    Use of glycoprotein IIb/IIIa inhibitor   196 (21.8)          83 (18.4)           0.151^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
  Diagnosis on admission                                                             
    Unstable Angina                          524 (58.2)          196 (43.5)          \<0.001^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    NSTEMI                                   377 (41.8)          255 (56.5)          
  PCI details                                                                        
    Left main disease                        74 (8.2)            53 (11.8)           0.035^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Three-vessel disease                     185 (20.5)          122 (27.1)          0.007^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Intra-aortic balloon pump                4 (0.4)             5 (1.1)             0.156^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    TIMI flow grade 3 post PCI               900 (99.9)          451 (100.0)         0.479^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Aspirin                                  895 (99.3)          448 (99.3)          0.999^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Clopidogrel                              768 (85.2)          384 (85.1)          0.963^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Ticagrelor                               124 (13.8)          62 (13.7)           0.994^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Statin                                   885 (98.2)          441 (97.8)          0.577^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    ACEI/ARBs                                518 (57.5)          282 (62.5)          0.076^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^
    Beta-blockers                            478 (53.1)          266 (59.0)          0.039^[a](#tfn2-etm-0-0-7890){ref-type="table-fn"}^

Values are expressed as median (interquartile range), n (%), or mean ± standard deviation.

P-values were calculated using Chi-square test.

P-values were calculated using Mann-Whitney U-test.

P-values were calculated using independent-samples t-test. MI, myocardial infarction; bpm, beats per min; H/LDL, high/low-density lipoprotein; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; NSTEMI, non-ST-segment elevation myocardial infarction; ACEI/ARBs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; TIMI, thrombolysis in myocardial infarction; FAR, fibrinogen-to-albumin ratio.

###### 

Major adverse cardiovascular events during the 1-year follow-up.

  Outcome                              Low FAR (n=901)   High FAR (n=451)   P-value
  ------------------------------------ ----------------- ------------------ ---------
  All-cause mortality                  12 (1.3)          21 (4.7)           \<0.001
  Cardiac mortality                    10 (1.1)          17 (3.8)           0.001
  Non-fatal reinfarction               10 (1.1)          6 (1.3)            0.724
  Unplanned repeat revascularization   35 (3.9)          16 (3.5)           0.759

Values are expressed as n (%). P-values were calculated using the Chi-square test. FAR, fibrinogen-to-albumin ratio.

###### 

Effects of the fibrinogen-to-albumin ratio (third vs. first and second tertile) on clinical outcomes according to univariate and multivariate analysis.

                                       Univariate analysis   Multivariate analysis                         
  ------------------------------------ --------------------- ----------------------- --------------------- -------
  All-cause mortality                  3.562 (1.752,7.239)   \<0.001                 2.223 (1.002,4.931)   0.049
  Cardiac mortality                    3.450 (1.580,7.535)   0.002                   2.336 (0.966,5.649)   0.060
  Non-fatal reinfarction               0.913 (0.505,1.650)   0.763                                         
  Unplanned repeat revascularization   1.204 (0.438,3.314)   0.719                                         

Univariate and multivariate Cox proportional hazard models were used to analyse the effects of variables on event-free survival. HR, hazard ratio; CI, confidence interval.
